Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Davids

Showing results (11-20 of 224) with videos related to

Pageof 23
Sort By:
American Journal of Hematology|June 8, 2017
IGHV mutational status testing in chronic lymphocytic leukemiaJennifer Crombie, Matthew S Davids
Future Oncology (London, England)|May 12, 2017
Venetoclax for the treatment of patients with chronic lymphocytic leukemiaJennifer Crombie, Matthew S Davids
Blood|July 29, 2025
How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitorMazyar Shadman, Matthew S Davids
Cancer Cell|February 16, 2013
ABT-199: taking dead aim at BCL-2Matthew S Davids, Anthony Letai
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Targeting the B-cell lymphoma/leukemia 2 family in cancerMatthew S Davids, Anthony Letai
Cancer Biology & Therapy|July 2, 2010
The molecular pathogenesis of myelodysplastic syndromesMatthew S Davids, David P Steensma
Hematological Oncology|June 15, 2025
Advances in the Management of Relapsed/Refractory CLL and Richter TransformationNathalie Javidi-Sharifi, Matthew S Davids
Hematology. American Society of Hematology. Education Program|December 10, 2017
Safety profiles of novel agent therapies in CLLInhye E Ahn, Matthew S Davids
Current Hematologic Malignancy Reports|January 25, 2017
The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic LeukemiaBenjamin L Lampson, Matthew S Davids
Open Journal of Hematology|July 31, 2012
Cell Trafficking in Chronic Lymphocytic LeukemiaMatthew S Davids, Jan A Burger
Pageof 23

Showing results (11-20 of 224) with videos related to

Sort By:
Pageof 23
American Journal of Hematology|June 8, 2017
IGHV mutational status testing in chronic lymphocytic leukemiaJennifer Crombie, Matthew S Davids
Future Oncology (London, England)|May 12, 2017
Venetoclax for the treatment of patients with chronic lymphocytic leukemiaJennifer Crombie, Matthew S Davids
Blood|July 29, 2025
How I treat patients with CLL after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitorMazyar Shadman, Matthew S Davids
Cancer Cell|February 16, 2013
ABT-199: taking dead aim at BCL-2Matthew S Davids, Anthony Letai
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2012
Targeting the B-cell lymphoma/leukemia 2 family in cancerMatthew S Davids, Anthony Letai
Cancer Biology & Therapy|July 2, 2010
The molecular pathogenesis of myelodysplastic syndromesMatthew S Davids, David P Steensma
Hematological Oncology|June 15, 2025
Advances in the Management of Relapsed/Refractory CLL and Richter TransformationNathalie Javidi-Sharifi, Matthew S Davids
Hematology. American Society of Hematology. Education Program|December 10, 2017
Safety profiles of novel agent therapies in CLLInhye E Ahn, Matthew S Davids
Current Hematologic Malignancy Reports|January 25, 2017
The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic LeukemiaBenjamin L Lampson, Matthew S Davids
Open Journal of Hematology|July 31, 2012
Cell Trafficking in Chronic Lymphocytic LeukemiaMatthew S Davids, Jan A Burger
Pageof 23